Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
https://doi.org/10.14412/1996-7012-2015-3-16-20
Abstract
Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).
Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).
Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.
Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle.
About the Authors
T. A. Raskina
Kemerovo State Medical Academy, Ministry of Health of Russia
Russian Federation
22A, Voroshilov St., Kemerovo 650000
Russian Federation
22A, Voroshilov St., Kemerovo 650000
M. V. Koroleva
Kemerovo State Medical Academy, Ministry of Health of Russia
Russian Federation
22A, Voroshilov St., Kemerovo 650000
Russian Federation
22A, Voroshilov St., Kemerovo 650000
I. S. Dydykina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
O. S. Malyshenko
Kemerovo State Medical Academy, Ministry of Health of Russia
Russian Federation
22A, Voroshilov St., Kemerovo 650000
Russian Federation
22A, Voroshilov St., Kemerovo 650000
G. A. Pintova
Research Institute for Complex Problems of Hygiene and Occupational Diseases
Russian Federation
23, Kutuzov St., Novokuznetsk 654041
Russian Federation
23, Kutuzov St., Novokuznetsk 654041
References
1. Дыдыкина ИС, Алексеева ЛИ. Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение. Научно-практическая ревматология. 2011;49(5):13–7. [Dydykina IS, Alekseeva LI. Osteoporosis in rheumatoid arthritis: diagnosis, risk factors, fractures, treatment. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(5):13–7. (In Russ.)]. doi: http://dx.doi.org/10.14412/1995-4484-2011-1454
2. Каратеев ДЕ, Раденска-Лоповок СГ, Насонова ВА. Синовиальная оболочка на ранней стадии ревматоидного артрита: клинико-морфологические сопоставления. Терапевтический архив. 2003;(5):12–20. [Karateev DE, RadenskaLopovok SG, Nasonova VA. Synovium in early rheumatoid arthritis: clinical and morphological comparisons. Terapevticheskii arkhiv. 2003;(5):12–20. (In Russ.)].
3. РаскинаТА, Летаева МВ. Минеральная плотность костной ткани у мужчин при различных клинических вариантах ревматоидного артрита. Научно-практическая ревматология. 2011;49(2):21–4. [RaskinaTA, Letaeva MV. Bone mineral density in males with different clinical types of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(2):21–4. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2011-598
4. Лесняк ОМ, Беневоленская ЛИ. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Москва: ГЭОТАР-Медиа;2011. 270 с. [Lesnyak OM, Benevolenskaya LI. Osteoporoz. Diagnostika, profilaktika i lechenie. Klinicheskie rekomendatsii [Osteoporosis. Diagnosis, prevention and treatment. Clinical guidelines]. Moscow: GEOTAR-Media;2011. 270 p.]
5. Goldring SR. The effects of inflammatory arthritis on bone remodeling. Arthritis Res Ther. 2005;7(Suppl 1):S12. DOI 10.1186/ar1518
6. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006 Jan;12(1):17–25. Epub 2005 Dec 13.
7. Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. Научно-практическая ревматология. 2009;1(прил):3–22. [Nasonov EL. The use of rituximab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;1(suppl):3–22. (In Russ.)].
8. Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС;2012. 344 с. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS;2012. 344 p.]
9. Kanis JA, Johanson Н, Oden А, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893–9. Epub 2004 Jan 27.
10. Григорьева НВ. Метотрексат и костная ткань. Новости медицины и фармации. 2009;19(293). [Grigor'eva NV. Methotrexate and bone. Novosti meditsiny i farmatsii. 2009;19(293). (In Russ.)].
11. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor (B ligand in serum of rheumatoid arthritis and their normalization after antitumor necrosis factor a treatment. Arthritis Rheum. 2002 Jul;46(7):1744–53.
12. Cohen SB, Emery P, Greenwald MW, еt al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary effectiveness and safety at twenty-four weeks. Arthritis Rheum. 2006 Sep;54(9):2793–806.
13. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcоmes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011 Jan;70(1):39–46. doi: 10.1136/ard.2010.137703. Epub 2010 Oct 11.
14. Boumans MJ, Thurlings RM, Yeo L, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012 Jan;71(1): 108–13. DOI: 10.1136/annrheumdis-2011-200198. Epub 2011 Nov 8.
15. Wheater G, Hogan VE, Teng YK, et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int. 2011 Dec;22(12):3067–72. doi: 10.1007/s00198-011-1607-0. Epub 2011 Apr 6.
Review
For citations:
Raskina TA, Koroleva MV, Dydykina IS, Malyshenko OS, Pintova GA. Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;9(3):16-20. (In Russ.) https://doi.org/10.14412/1996-7012-2015-3-16-20
Views:
1295
Email this article 